Source of Neurally-Mediated Hand Weakness After Stroke
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Hines |
| State: |
|
Illinois |
| Zip Code: |
|
60141 |
| Conditions: |
|
Stroke - Cerebrovascular Accident |
| Purpose: |
|
The purpose of this study is to determine whether neural block and neuromuscular electrical
stimulation are effective in treating finger impairment due to stroke.
|
| Study Summary: |
|
The incidence of stroke-induced hemiparesis among veterans is likely to rise as this
population ages. Post-stroke hemiparesis is often marked by persistent hand impairment,
which adversely affects both a person's ability to work and his/her quality of life. We
believe that impairment is primarily due to neural, rather than biomechanical, factors. At
the muscle level, these factors relate either to the inability to activate muscles (i.e.,
low muscle activation) or to activate them appropriately (i.e., abnormal muscle
co-activation). Currently it is unclear as to which one is largely responsible for weakness
in the hand as the net mechanical effect, e.g., reduced fingertip force production, could be
the same. Determination of voluntary muscle force generation could help to explain deficits
in fingertip force production in specific directions, as well as to customize treatment
approaches in which force generation ability of some muscles is decreased and others
increased. The goal of this work is to explain the source of neurally-mediated weakness at
the fingertip following hemiparetic stroke, and to design and experimentally test
rehabilitation interventions that attempt to offset this weakness.
|
| Criteria: |
|
Inclusion Criteria:
- clinical diagnosis of stroke;
- stroke occurred no less than 6 months prior to study;
- must have had only 1 stroke;
- must demonstrate severe hand impairment;
- must have no substantial evidence of motor and sensory deficits in non-paretic limb;
- must have no history or clinical signs of neurologic diseases other than stroke;
- must have no cognitive dysfunction that precludes comprehension of experimental
tasks;
- must be able to give informed consent
Exclusion Criteria:
- taking medication that can increase the risk of lidocaine toxicity such as cimetidine
(ulcer treatment drug), phenytoin (anticonvulsant drug), nadolol (drug for treatment
of headache, hypertension, chest pain);
- taking anticoagulant medication, i.e., aspirin, coumadin;
- has a low platelet count or a bleeding disease
|
| NCT ID: |
|
NCT00907829 |
| Primary Contact: |
|
Principal Investigator
Joseph Towles
Edward Hines Jr. VA Hospital
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Hines, Illinois 60141
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|